Akkermansia muciniphila Alleviates Sarcopenia in Senescence-Accelerated Mouse-Prone 8 Mice
Journal of Microbiology and Biotechnology · 26.08.2025 · 35
DOI: 10.4014/jmb.2507.07001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Microbiology and Biotechnology, online erschienen am 26.08.2025. Verfasst von So-Hyun Park und 6 weiteren Autor:innen. Beteiligte Einrichtung: Aging and Metabolism Research Group, Korea Food Research Institute, Wanju 55365, Republic of Korea. Hauptthemen laut MEDLINE: Sarcopenia, Probiotics, Aging. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Korea Food Research Institute, Ministry of Science and ICT, South Korea.
Abstract (Originalsprache)
Akkermansia muciniphila, an intestinal bacterium, has garnered attention for its association with metabolic health and anti-inflammatory properties. However, its potential role in mitigating sarcopenia, particularly in the senescence-accelerated mouse-prone 8 (SAMP8) model, remains unexplored. In this study, we aimed to evaluate the potential effects of A. muciniphila supplementation on sarcopenia and its underlying mechanisms. Seven-month-old SAMP8 mice were administered A. muciniphila for 3 months. A. muciniphila supplementation enhanced grip strength and skeletal muscle mass, suppressed cellular senescence, improved the balance between protein degradation and synthesis, increased total ATP, and improved mitochondrial biogenesis. Analysis of the effects of A. muciniphila on gut microbiome using 16S rRNA sequencing showed that supplementation with A. muciniphila shifted the gut microbiota composition, alleviated gut dysbiosis, preserved gut barrier integrity, and reduced the protein expression of inflammatory cytokines in the intestine. Additionally, extracellular vesicles derived from A. muciniphila promoted myogenesis and suppressed dexamethasone-induced atrophy in C2C12 myoblasts. These findings suggest that supplementation with A. muciniphila mitigates sarcopenia by suppressing inflammation and improving the gut microenvironment, highlighting the potential of A. muciniphila as a new therapeutic candidate to treat sarcopenia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Aging and Metabolism Research Group, Korea Food Research Institute, Wanju 55365, Republic of Korea.
- Department of Food Biotechnology, University of Science and Technology, Wanju 55365, Republic of Korea.
- Electron Microscopy Research Center, Korea Basic Science Institute, Ochang 28119, Republic of Korea.
Förderung
- Korea Food Research Institute
- Ministry of Science and ICT, South Korea
Zitieren
APA
Park, S. H., Kim, H. S., Choi, P. G., Jeong, M. S., Huh, Y. H., Ahn, J., & Jung, C. H. (2025). Akkermansia muciniphila Alleviates Sarcopenia in Senescence-Accelerated Mouse-Prone 8 Mice. Journal of Microbiology and Biotechnology, 35. https://doi.org/10.4014/jmb.2507.07001
Vancouver
Park SH, Kim HS, Choi PG, Jeong MS, Huh YH, Ahn J, et al. Akkermansia muciniphila Alleviates Sarcopenia in Senescence-Accelerated Mouse-Prone 8 Mice. Journal of Microbiology and Biotechnology. 2025;35. doi:10.4014/jmb.2507.07001
BibTeX
@article{Park2025,
author = {Park, So-Hyun and Kim, Hee Soo and Choi, Pyeong Geun and Jeong, Myeong Seon and Huh, Yang Hoon and Ahn, Jiyun and Jung, Chang Hwa},
title = {Akkermansia muciniphila Alleviates Sarcopenia in Senescence-Accelerated Mouse-Prone 8 Mice},
journal = {Journal of Microbiology and Biotechnology},
year = {2025},
volume = {35},
doi = {10.4014/jmb.2507.07001}
}
EUVIMED